

# The animal intensive care unit – how to design animal experiments in shock research

*Peter Radermacher, Pierre Asfar*



# Do we need the „Animal ICU“?

Large vs. small animal models?

How long should animal models last?

Pre-existing co-morbidity?

Translation to the clinics?

"....Longer experiments with more advanced supportive care would allow better mimicry of the later stages of sepsis and multiorgan failure, permitting the testing of drugs in a more realistic setting...."

"....For example, options to enrich the pre-clinical portfolio include the study of animals that are more genetically diverse, are older, or have preexisting disease...."

**Marini et al: Critical care evidence – new directions.**

**JAMA 2015;313:893**


"....Development of appropriate experimental animal models or other preclinical research models should be considered a high priority of future research agendas...."



**Traber DL : *Expired nitric oxide and shock in higher order species.* Crit Care Med**

**1999;27:255**

**“...Would you as a critical care physician accept data on a septic patient who was not resuscitated? Would you accept data from a drug study on an intensive care patient who was not only not resuscitated with fluid but who did not even have blood pressures and heart rates monitored?... If the animals are resuscitated, is the resuscitation to a specific physiologic variable?... The pathophysiology and outcome of an unresuscitated, unmonitored, septic patient is certainly different....”**



**Control group**

Hollenberg SM et al:  
 Characterization of a  
 hyperdynamic murine model  
 of resuscitated sepsis using  
 echocardiography.  
*AJRCCM* 2001;164:891-5

**CLP+fluids  
 +antibiotics**

**CLP+antibiotics**

**CLP+fluids**

**CLP no therapy**

# Do we need the „Animal ICU“?

**Yes!**

How long should animal models last?

Pre-existing co-morbidity?

Translation to the clinics?

Do we need the „Animal ICU“?

**Large vs. small animal models?**

How long should animal models last?

Pre-existing co-morbidity?

Translation to the clinics?

## Mice as models for ALI/ARDS/shock

**Pro:**

- Genetically-modified strains available
- Homogeneous groups:
  - Incest strains -> little genetical variability
  - Gender selection possible
  - Young, healthy or specific co-morbidity, age
- Easy control of body temperature
- Numerous test systems available

**Con:**

- Size -> small blood volume, difficult instrumentation
- „non-shivering“ thermogenesis
- different mediator release/response

# Genomic responses in mouse models poorly mimic human inflammatory diseases

Junhee Seok<sup>a,1</sup>, H. Shaw Warren<sup>b,1</sup>, Alex G. Cuenca<sup>c,1</sup>, Michael N. Mindrinos<sup>a</sup>, Henry V. Baker<sup>c</sup>, Weihong Xu<sup>a</sup>, Daniel R. Richards<sup>d</sup>, Grace P. McDonald-Smith<sup>e</sup>, Hong Gao<sup>a</sup>, Laura Hennessy<sup>f</sup>, Celeste C. Finnerty<sup>g</sup>, Cecilia M. López<sup>c</sup>, Shari Honari<sup>f</sup>, Ernest E. Moore<sup>h</sup>, Joseph P. Minei<sup>i</sup>, Joseph Cuschieri<sup>j</sup>, Paul E. Bankey<sup>k</sup>, Jeffrey L. Johnson<sup>h</sup>, Jason Sperry<sup>l</sup>, Avery B. Nathens<sup>m</sup>, Timothy R. Billiar<sup>l</sup>, Michael A. West<sup>n</sup>, Marc G. Jeschke<sup>o</sup>, Matthew B. Klein<sup>j</sup>, Richard L. Gamelli<sup>p</sup>, Nicole S. Gibran<sup>j</sup>, Bernard H. Brownstein<sup>q</sup>, Carol Miller-Graziano<sup>k</sup>, Steve E. Calvano<sup>r</sup>, Philip H. Mason<sup>e</sup>, J. Perren Cobb<sup>s</sup>, Laurence G. Rahme<sup>t</sup>, Stephen F. Lowry<sup>r,2</sup>, Ronald V. Maier<sup>j</sup>, Lyle L. Moldawer<sup>c</sup>, David N. Herndon<sup>g</sup>, Ronald W. Davis<sup>a,3</sup>, Wenzhong Xiao<sup>a,t,3</sup>, Ronald G. Tompkins<sup>t,3</sup>, and the Inflammation and Host Response to Injury, Large Scale Collaborative Research Program<sup>4</sup>

PNAS 2013;110:3507

# Genomic responses in mouse models greatly mimic human inflammatory diseases

PNAS 2015;112:1167

Keizo Takao<sup>a,b</sup> and Tsuyoshi Miyakawa<sup>a,b,c,1</sup>

## ABANDON THE MOUSE RESEARCH SHIP? NOT JUST YET!

Marcin F. Osuchowski<sup>1,a</sup>, Daniel G. Remick<sup>2</sup>, James A. Lederer<sup>3</sup>, Charles H. Lang<sup>4</sup>, Ansgar O. Aasen<sup>5</sup>, Mayuki Aibiki<sup>6</sup>, Luciano C. Azevedo<sup>7</sup>, Soheyl Bahrami<sup>1</sup>, Mihaly Boros<sup>8</sup>, Robert Cooney<sup>9</sup>, Salvatore Cuzzocrea<sup>10</sup>, Yong Jiang<sup>11</sup>, Wolfgang G. Junger<sup>12</sup>, Hiroyuki Hirasawa<sup>13</sup>, Richard S. Hotchkiss<sup>14</sup>, Xiang-An Li<sup>15</sup>, Peter Radermacher<sup>16</sup>, Heinz Redl<sup>1</sup>, Reinaldo Salomao<sup>17</sup>, Amin Soebandrio<sup>18</sup>, Christoph Thiemermann<sup>19</sup>, Jean-Louis Vincent<sup>20</sup>, Peter Ward<sup>21</sup>, Yong-Ming Yao<sup>22</sup>, Huang-Ping Yu<sup>23</sup>, Basilia Zingarelli<sup>24</sup>, and Irshad H. Chaudry<sup>25,a</sup>

Shock 2014;41:463

## human volunteers:

- 4 ng/kg bolus (Preas et al, AJRCCM 2001; 164:620)
- 2 ng/kg bolus (Michaeli et al, Clin Nutr 2007;26:70)

## Mice, endotoxin-induced acute lung injury:

- 0.4 mg/kg bolus nasal (Dreymüller et al, EMBO Mol Med 2012;4:412)
- 1.5 mg/kg bolus i.v. (Mangalmurti et al, Blood 2009;113:1158)
- 4 mg/kg bolus intratracheal (Mekontso-Dessap et al, AJRCBM 2012;46:541)

## Pigs, endotoxin-induced „septic“ shock:

- 10-40 ng/kgxmin infusion (Hauser et al, CCM 2005;33:2034)

# NO metabolites

## Human septic shock:

- **$77 \pm 10 \mu\text{M}$  (controls:  $29 \pm 4$ ; non-septic trauma  $13 \pm 2 \mu\text{M}$ )** (Ochoa et al, Ann Surg 1991;32:13)
- **47 (28-77)  $\mu\text{M}$**  (Watson et al, CCM 2004;32:13)

## Mice, CLP-induced septic acute lung injury:


- **102 (47-121)  $\mu\text{M}$**  (Barth et al, CCM 2006;34:307)
- **$161 \pm 23 \mu\text{M}$**  (Wang et al, Am J Pathol 2012;180:505)

## Pigs, fecal peritonitis-induced septic shock:


- **17 (11-30)  $\mu\text{M}$  (before shock: 21 (12-48)  $\mu\text{M})$**  (Simon et al, Crit Care 2009;13:R113)

*Godin DV, Garnett ME:*

**Species-related variations in tissue antioxidant status – II. Differences in susceptibility to oxidative stress.** *Comp Biochem Physiol B* 1992;103:743; **Species-related variations in tissue antioxidant status – I. Differences in anti-oxidant profiles.** *Comp Biochem Physiol B* 1992;103:737



## Anatomical and Physiological Similarities of the Kidney

Mice, rats and rabbits	Pig , monkeys and HUMANS
<ul style="list-style-type: none"> <li>• Unilobular, unipapillar kidney</li> <li>• Urine empties directly into renal pelvis (no branched calicacal network)</li> <li>• Segmental arteries are bypassed</li> </ul> 	<ul style="list-style-type: none"> <li>• Multilobular, multipapillary kidney</li> <li>• Urine empties into calicacal network into renal pelvis</li> <li>• Interlobular and segmental arteries</li> </ul>  

# The „Mouse Intensive Care Unit“-concept



Inspiratory/expiratory  
 $\text{CO}_2/\text{O}_2$ : calorimetry

$^{13}\text{CO}_2$ -  
Infrared-  
Spectrometry

Tracheostomy

LV pressure-  
volume loops

Catheter  
*A. carotis*

Closed-loop  
body temperature  
control

Temperature  
probe

Remission-  
spectrophotometry  
Laser-Doppler-  
Flowmetry

Catheter  
*V.  
jugularis*

Anesthetics

Colloids

Noradrenaline

$^{13}\text{C}_6$ -glucose-isotope

Liver

Bladder  
catheter

*A. mes. sup.*




*V. portae*

Ultrasound-Doppler  
flowmetry

Catheter  
*A. femoralis*

Arterial  
pressure,  
heart rate

Urine output,  
Creatinine clearance







# Recurrent Recruitment Manoeuvres Improve Lung Mechanics and Minimize Lung Injury during Mechanical Ventilation of Healthy Mice

PLoS ONE 6(9): e24527, 2011

Lucy Kathleen Reiss\*, Anke Kowallik, Stefan Uhlig

Mice, 6 hrs;  $\text{FiO}_2$  0.5, RR 180/min,  $V_t$  8 mL/kg, PEEP 6 cmH<sub>2</sub>O,  
Recruitment 30 cmH<sub>2</sub>O/1 sec every 5 / 60 min vs. *no recruitment*





Cardiopulmonary, Histologic, and Inflammatory Effects of  
Wagner et al: Intravenous Na<sub>2</sub>S After Blunt Chest Trauma-Induced Lung  
Contusion in Mice*J Trauma.* 2011;71: 1659Total lung injury score ( $\Sigma$  dystelectasis/atelectasis + edema/hemorrhage + leukocyte infiltration +  
thickened alveolar membrane)

	Hert rate (beats/min)	MAP (mmHg)	pH	Cpl ( $\mu$ L/cmH <sub>2</sub> O)	PaO <sub>2</sub> /FiO <sub>2</sub> (mmHg)
Start	<b>325</b> (311;350)	<b>60</b> (58;71)	<b>7.31</b> (7.27;7.33)	<b>64</b> (60;71)	<b>362</b> (314;510)
End (4 h)	<b>370</b> (340;441)	<b>72</b> (66;78)	<b>7.38</b> (7.35;7.42)	<b>70</b> (64;81)	<b>564</b> (456;614)

# The „Pig Intensive Care Unit“-Concept





Ventral view of the abdominal viscera of the pig *in situ*.



Glucose oxidation  
Expiratory  $^{13}\text{CO}_2$



Swan-Ganz-catheter

Lactat clearance  
Bilirubin  
ASAT, ALAT  
Gluconeogenesis  
(Ra of  $^{13}\text{C}_6$ -glucose)

Suprapubic catheter  
A. Femoralis catheter  
Transpulmonary thermodilution (PICCO)

Creatinine-clearance,  
fractional  $\text{Na}^+$ -extraction

% $\text{SpO}_2$   
Et  $\text{CO}_2$


Central venous  
catheter  
ECG


LV-pressure-conductance  
catheter: PV-loops

A. renalis  
A. hepatica  
V portae

Doppler Ultrasound

V. renalis  
catheter






### Measurements:

- **Modified Glasgow Coma Scale**
- **Response to painful stimuli**
- Microdialysis for glutamate, pyruvate, lactate and glucose
- bilateral measurement of ICP (CPP), p<sub>t</sub>O<sub>2</sub> and temperature
- Mitochondrial respiration and ROS production in PBMCs and neutrophils
- Electron spin resonance

### Post-mortem:

- Nissl-Staining
- Western blots
- Immunohistochemistry
- High resolution respirometry






*George E.P. Box, FRS (1919-2013):*  
**'All models are wrong,  
but some are useful'**

*Tucker A, et al:*

# Lung vascular smooth muscle as a determinant of pulmonary hypertension at high altitude.

*Am J Physiol 1975;228:762*


Species	Control	Altitude (4500m)
<b>Sheep 42 days</b>	<b><math>20 \pm 1</math></b>	<b><math>23 \pm 2</math></b>
<b>Dog 42 days</b>	<b><math>26 \pm 2</math></b>	<b><math>28 \pm 1</math></b>
<b>Pig 42 days</b>	<b><math>27 \pm 1</math></b>	<b><math>72 \pm 7</math></b>



*Kuriyama , et al:*

## Role of collateral ventilation in ventilation-perfusion imbalance. *J Appl Physiol 1984;56:1500*

Dogs, pigs; isolated lung region  $\text{FiO}_2$  13 %, remainder 30 %:  
Presence or not of alveolar collateral ventilation



# Do we need the „Animal ICU“?

## Large vs. small animal models?

**Both!**

## Pre-existing co-morbidity?

## Translation to the clinics?

Do we need the „Animal ICU“?

Large vs. small animal models?

**How long should animal models last?**

Pre-existing co-morbidity?

Translation to the clinics?

*Su et al:*

# Epidemiology of sepsis in Germany: results from a national prospective multicenter study.

*Intensive Care Med 2007;33:606-18*

## ICU length of stay 12 - 19 days

Jesús Villar  
Jesús Blanco  
José Manuel Añón  
Antonio Santos-Bouza  
Lluís Blanch  
Alfonso Ambrós  
Francisco Gandía  
Demetrio Carriedo  
Fernando Mosteiro  
Santiago Basaldúa  
Rosa Lidia Fernández  
Robert M. Kacmarek  
on behalf of the ALIEN Network

**The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation**

*Intensive Care Med (2011) 37:1932*

Hospital	ICU	Mechanical Ventilation
<b>35</b> (19-64)	<b>22</b> (13-36)	<b>17</b> (10-29)



*Benes et al:* Searching for mechanisms that matter in early septic acute kidney injury: an experimental study. *Crit Care* 2011;15:R256 **swine**

**22h**

*Su et al:* Effects of a selective iNOS inhibitor versus norepinephrine in the treatment of septic shock. *Shock* 2010;34:243-9 **sheep**

**24h**

*Lange et al:* Time course of nitric oxide synthase, nitrosative stress, and poly(ADP ribosylation) in an **ovine** sepsis model. *Crit Care* 2010;14:R129

**24h**

*Vuda et al:* Effects of catecholamines on hepatic and skeletal muscle mitochondrial respiration after prolonged exposure to faecal peritonitis in **pigs**. *Innate Immun* 2011;1-14

**27h**

*Correa et al:* Increasing mean arterial blood pressure in sepsis: effects on fluid balance, vasopressor load and renal function. *Crit Care* 2013;17:R21 **swine**

**48h**

*Horst et al:* Characterization of blunt chest trauma in a long-term **porcine** model of severe multiple trauma. *Sci Rep* 2016;6:39659

**72h**

*Esechie et al:* Beneficial effect of hydrogen sulphide donor (sodium sulphide) in an **ovine** model of burn- and smoke-induced acute lung injury. *Br J Pharmacol* 2009;158:1442-53

**96h**

*Bogdanski et al:* Cerebral histopathology following portal venous infusion of bacteria in a chronic **porcine** model. *Anesthesiology* 2000;93:793-804

**104h**

# Do we need the „Animal ICU“?

## Large vs. small animal models?

## How long should animal models last?

**As long as possible!?!?**

## Translation to the clinics?

Do we need the „Animal ICU“?

Large vs. small animal models?

How long should animal models last?

**Pre-existing co-morbidity?**

Translation to the clinics?

# Severe Sepsis and Septic Shock



Derek C. Angus, M.D., M.P.H., and Tom van der Poll, M.D., Ph.D.

N Engl J Med 2013;369:840-51

„.... For example, options to enrich the pre-clinical portfolio include the study of animals that are more genetically diverse, are older, or have preexisting disease. ....“

7. FEBRUAR 2013 DIE ZEIT N°7

# Woran wir sterben




Unter dem Titel »Global Burden of Disease« wurden erstmals 1992 alle Menschen erfasst, die innerhalb des Jahres gestorben waren. Außerdem beschrieb die Studie die wichtigsten Risikofaktoren für die Gesundheit. Vor einem Monat wurde nun, zwanzig Jahre später, eine Folgestudie veröffentlicht, basierend auf den knapp 53 Millionen Todesfällen des Jahres 2010. Das Fazit: Die Bevölkerung ist in der Zwischenzeit deutlich gesünder geworden. Infektionskrankheiten wurden zurückgedrängt, dafür sterben mehr Menschen an Altersgebrechen und Zivilisationsleiden

<b>Stroke</b> $5.8 \cdot 10^6$	<b>24 %</b>
<b>MI</b> $7.0 \cdot 10^6$	
<b>COPD</b> $3.8 \cdot 10^6$	<b>7 %</b>
<b>Diabetes</b> $1.3 \cdot 10^6$	<b>2.5 %</b>




**Roth Händle**  
**4 days / week over 3-4 weeks**



*Hartmann et al:*



In-depth characterization of the effects of cigarette smoke exposure on the acute trauma response and haemorrhage in mice.

*Shock, doi: 10.1097/SHK.0000000000001115*




# Human-like atherosclerosis in minipigs: a new model for detection and treatment of vulnerable plaques

Troels Thim



Pigs with pre-existing atherosclerosis:  $\text{FiO}_2 1.0$  vs. standard treatment during the first 24 h (of 48 h) after 3-h hemorrhage



Do we need the „Animal ICU“?

Large vs. small animal models?

How long should animal models last?

Pre-existing co-morbidity?

**Must be included!**

Do we need the „Animal ICU“?  
Large vs. small animal models?  
How long should animal models last?  
Pre-existing co-morbidity?  
**Translation to the clinics?**

*Träger et al.*

**Norepinephrine and  $N^{\omega}$ -monomethyl-L-arginine in porcine septic shock: effects on hepatic  $O_2$  exchange and energy balance.**

*Am J Respir Crit Care Med 1999;159:1758*

In summary, L-NMMA and NOR were equally effective in maintaining MAP during long-term hyperdynamic porcine endotoxic shock.

*López et al.*

**Multi-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock.**

*CCM 2004;32:21*

***Conclusions:*** In this study, the nonselective nitric oxide synthase inhibitor 546C88 increased mortality in patients with septic shock.

*Simon et al.*

**Comparison of cardiac, hepatic and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized, controlled trial. *Crit Care* 2009;13:R113**

Low-dose AVP appears to be safe with respect to myocardial function and heart injury and even attenuates kidney and liver dysfunction and tissue damage during well-resuscitated porcine septic shock.

*Gordon et al.*

**Effect of early vasopressin vs. norepinephrine on kidney failure in patients with septic shock. The VANISH randomized clinical trial.**

*JAMA* 2016;316:509

.... Although these findings do not support the use of vasopressin to replace norepinephrine as initial treatment in this situation, the confidence interval included a potential clinically important benefit for vasopressin....

**Hauser et al.** Hemodynamic, metabolic and organ function effects of pure O<sub>2</sub> ventilation during established fecal peritonitis-induced septic shock. *CCM* 2009;37:2465

**Conclusions:** During early hyperdynamic porcine septic shock, 100% oxygen improved organ function and attenuated tissue apoptosis without affecting lung function and oxidative or nitrosative stress. Therefore, it might be considered as an additional measure in the first phase of early goal-directed therapy.

**Conclusions:** When compared with the previous report on hyperoxia initiated simultaneously with induction of sepsis, i.e., using a pretreatment approach, pure oxygen ventilation started when porcine fecal peritonitis-induced septic shock was fully developed proved to be equally safe with respect to lung function and oxidative stress, but exerted only moderate beneficial effects.

**Asfar et al.** Hyperoxia and hypertonic saline in patients with septic shock: A randomized clinical trial. *Lancet Respir Med* 2017;5:180

.... total SOFA was significantly lower by day 7 (table 2) and the liver SOFA score was significantly lower from day 3 to day 7 .... In conclusion, in patients with septic shock, hyperoxia and hypertonic saline used as fluid resuscitation did not reduce the mortality at either 28 days or 90 days. ....

*Osuchowski et al.*

**Minimum quality threshold in pre-clinical sepsis studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis.**

*Intensive Care Med Exp 2018;6:26*

*Zingarelli et al.*

**Part I: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for Study Design and Humane Modeling Endpoints.**  
*Shock 2019;51:10-22*

*Libert et al.*

**Part II: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for Types of Infections and Organ Dysfunction Endpoints.**  
*Shock 2019;51:23-32*

*Hellman et al.*

**Part III: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for Fluid Resuscitation and Antimicrobial Therapy Endpoints.**  
*Shock 2019;51:33-43*

